Document Type
Article
Publication Date
7-2025
Identifier
DOI: 10.1002/pbc.31744
Abstract
High-dose methotrexate dosage and infusion durations differ across treatment protocols for pediatric leukemia, lymphoma, and osteosarcoma. Supportive care interventions are dependent on a patient's elimination of methotrexate (MTX). Therefore, it is important to establish the expected MTX elimination across protocols. Using modeling and simulation of real-world data, we determined the expected MTX concentrations at common time points from the start of infusion (24, 36, 42, 48, 60, and 72 hours) and the time that each patient would reach a typical discharge threshold (0.4, 0.2, 0.15, and 0.10 µM). These data provide a reference for MTX concentrations for common pediatric protocols.
Journal Title
Pediatric blood & cancer
Volume
72
Issue
7
First Page
31744
Last Page
31744
MeSH Keywords
Humans; Methotrexate; Child; Drug Monitoring; Antimetabolites, Antineoplastic; Child, Preschool; Adolescent; Female; Male; Neoplasms; Infant
PubMed ID
40254820
Keywords
Leukemia; lymphoma; methotrexate; osteosarcoma; pediatrics; pharmacokinetics
Recommended Citation
Taylor ZL, Miller TP, Board SG, et al. What Is the Expected Clearance of Methotrexate? A Therapeutic Drug Monitoring Reference Guide for High-Dose Methotrexate Use in Pediatric Malignancies. Pediatr Blood Cancer. 2025;72(7):e31744. doi:10.1002/pbc.31744
Comments
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Publisher's Link: https://onlinelibrary.wiley.com/doi/10.1002/pbc.31744